Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli
Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli
Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Medicam<strong>en</strong>tos</strong> <strong>para</strong> <strong>prev<strong>en</strong>ir</strong> <strong>las</strong> <strong>cefaleas</strong> migrañosas <strong>en</strong> los niños<br />
Characteristics of included studies<br />
Study<br />
Methods<br />
Participants<br />
Interv<strong>en</strong>tions<br />
Outcomes<br />
Notes<br />
Allocation concealm<strong>en</strong>t<br />
Study<br />
Methods<br />
Participants<br />
Interv<strong>en</strong>tions<br />
Outcomes<br />
Notes<br />
Allocation concealm<strong>en</strong>t<br />
Battistella 1990<br />
TABLAS<br />
Randomised, double-blind, placebo-controlled, crossover.<br />
Randomisation not described. Active and placebo id<strong>en</strong>tical in colour.<br />
Migraine by IHS 1988.<br />
Symptomatic treatm<strong>en</strong>t permitted with acetaminoph<strong>en</strong>. Compliance not reported.<br />
37 randomised. 7 withdrawals.<br />
Groups A (15) and B (15) were com<strong>para</strong>ble for age, sex, type of headaches, frequ<strong>en</strong>cy<br />
and duration of attacks, and duration of illness before dropouts.<br />
16/30 males. Age range: 7 to 18 years.<br />
A: 4-week run-in, th<strong>en</strong> placebo for 12 weeks (T1), th<strong>en</strong> 4-week washout followed by<br />
nimodipine (10 mg: < 40 kg; 16 mg: 40-50 kg; 20 mg: > 50 kg) 3 times a day for 12<br />
weeks (T2).<br />
B: 4-week run-in, th<strong>en</strong> nimodipine (10 mg: < 40 kg; 16 mg: 40-50 kg; 20 mg: > 50 kg)<br />
3 times a day for 12 weeks (T1), th<strong>en</strong> 4-week washout followed by placebo for 12 weeks<br />
(T2).<br />
Frequ<strong>en</strong>cy and duration.<br />
No significant reduction of outcomes with nimodipine.<br />
7 withdrawals. 4 dropouts from Group A and 3 from B for reasons other than adverse<br />
ev<strong>en</strong>ts.<br />
Adverse ev<strong>en</strong>ts: 3 - mild abdominal discomfort.<br />
B<br />
Battistella 1993<br />
Randomised, double-blind, placebo-controlled, crossover.<br />
Randomisation not described. Active and control id<strong>en</strong>tical in colour.<br />
Migraine by IHS 1988.<br />
Symptomatic treatm<strong>en</strong>t permitted with acetaminoph<strong>en</strong>. Compliance not reported.<br />
40 randomised. 5 withdrawals.<br />
Groups A (18 pati<strong>en</strong>ts) and B (17 pati<strong>en</strong>ts) were com<strong>para</strong>ble for sex, age, history of<br />
disease, and frequ<strong>en</strong>cy and duration of attacks.<br />
22/35 males. Age range: 7 to 18 years.<br />
A: 4-week run-in, th<strong>en</strong> 12 weeks of trazodone 1 mg/kg/day in 3 divided doses (T1),<br />
th<strong>en</strong> 4-week washout, th<strong>en</strong> 12 weeks of placebo in 3 doses (T2).<br />
B: 4-week run-in, th<strong>en</strong> 12 weeks of placebo (T1), th<strong>en</strong> 4-week washout followed by 12<br />
weeks of trazodone 1 mg/kg/day in 3 divided doses (T2).<br />
Frequ<strong>en</strong>cy and duration.<br />
No significant reduction in outcomes with trazadone.<br />
5 withdrawals due to onset of other diseases or errors in administration.<br />
No serious adverse ev<strong>en</strong>ts. In particular, no changes in alertness, school performance,<br />
mood, or sleep-wake rhythms.<br />
B<br />
Página 20<br />
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.
Change language